

## Appendix 1.

### Included studies:

1. Akobeng AK, Miller V, Stanton J, Elbadri AM, Thomas AG. Double-blind randomized controlled trial of glutamineenriched polymeric diet in the treatment of active Crohn's disease. *Journal of Pediatric Gastroenterology and Nutrition* 2000;30(1):78–84.
2. Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G. Is maintenance therapy always necessary for patients with ulcerative colitis?. *Alimentary Pharmacology and Therapeutics* 1999;13:373-9.
3. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. *Digestive and Liver Disease* 2003;35:619-27. [PUBMED: 14563183]
4. Ardizzone S, Maconi G, Sampietro G, Russo A, Radice E, Colombo E, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. *Gastroenterology* 2004;127(3):730-40.
5. Arnold GI, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. *Inflammatory bowel diseases* 2002;8(1):10-5.
6. Arora S, Katkov W, Cooley J, Kemp JA, Johnston DE, Schapiro RH, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. *Hepatogastroenterology* 1999;46(27):1724-9. [PUBMED: 10430331]

7. Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, et al.  
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. *Gut* 2006; Vol. 55:1568-74.
8. Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, et al.  
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: A randomized trial. *Gastroenterology* 2008;134:1861-8.
9. Baert F, Schmit A, D'Haens G, Dedeurwaerdere F, Louis E, Cabooter M, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. *Gastroenterology* 2002;122(1):20-5.
10. Bamba T, Shimoyama T, Sasaki M, Tsujikawa T, Fukuda Y, Koganei K, et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. *European Journal of Gastroenterology & Hepatology* 2003;15(2):151-7.
11. Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, et al.  
Budesonide versus prednisone in the treatment of active Crohn's disease. *Gastroenterology* 1998;115(4):835-40.
12. Bartel G, Weiss I, Turetschek K, Schima W, Püspök A, Waldhoer T, et al. Ingested matter affects intestinal lesions in Crohn's disease. *Inflammatory Bowel Diseases* 2008;14(3):374-82. [PUBMED: 17932967]
13. Beeken W, Howard D, Bigelow J, Trainer T, Roy M, Thayer W, et al. Controlled trial of 4-ASA in ulcerative colitis. *Digestive Diseases and Sciences* 1997;42:354-8.

14. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *New England Journal of Medicine* 1996;334(24):1557-60.
15. Bhattacharyya S, Shumard T, Xie H, Dodda A, Varady KA, Feferman L, et al. A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity. *Nutrition and Healthy Aging* 2017;4:181–192.
16. de Bievre MA, Vrij AA, Schoon EJ, Dijkstra G, de Jong AE, Oberndorff-Klein AH, et al. Randomized, placebocontrolled trial of low molecular weight heparin in active ulcerative colitis. *Inflamm Bowel Dis* 2007;13(6):753–8. [PUBMED: 17260365]
17. Bloom S, Liilerich S, Lassen MR, Forbes A, Leiper K, Langholz E, et al. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. *Aliment Pharmacol Ther* 2004;19(8):871–8. [PUBMED: 15080848]
18. Bonderup OK, Hansen JB, Birket-Smith L, Vestergaard V, Teglbjaerg PS, Fallingborg J. Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. *Gut* 2003;52(2):248-51.
19. Bonderup OK, Hansen JB, Teglbjrg PS, Christensen LA, Fallingborg JF. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. *Gut* 2009;58(1):68-72.
20. Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. *Clinical Gastroenterology and Hepatology* 2006;4(6):744–53

21. Brotherton CS, Taylor AG, Bourguignon C, Anderson JG. A high-fiber diet may improve bowel function and health-related quality of life in patients with Crohn disease. *Gastroenterology Nursing* 2014;37(3):206-16. [PUBMED: 24871666]
22. Calabrese C, Fabbri A, Areni A, Zahlane D, Scialpi C, Febo G. Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. *Journal of Gastroenterology and Hepatology* 2007;22(6):809-14.
23. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. *Gut* 1997;41(2):209-14.
24. Caprilli R, Cottone M, Tonelli F, Sturniolo G, Castiglione F, Annese V, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind randomized controlled trial. *Alimentary Pharmacology & Therapeutics* 2003;17(4):517-23.
25. Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, et al. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a large proportion of patients with ulcerative colitis. *Gastroenterology* 2016;150(2):380-8.
26. Celasco G, Papa A, Jones R, Moro L, Bozzella R, Surace MM, et al. Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. *Aliment Pharmacol Ther* 2010;31(3):375-86. [PUBMED: 19891665].
27. Cezard JP, Munck A, Mouterde O, Morali A, Lenaerts C, Lachaux A, et al. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-

blind, randomized, placebo-controlled trial. *Gastroenterologie Clinique et Biologique* 2009;33:31-40.

28. Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. *American Journal of Gastroenterology* 1999;94(3):674-78.

29. Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. *New England Journal of Medicine* 2010;362(15):1383-95.

30. Cortot A, Colombel JF, Rutgeerts P, Lauritsen K, Malchow H, Hamling J, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. *Gut* 2001;48(2):186-90.

31. Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. *Gastroenterology* 2013;145(4): 758-65.e2; quiz e14-5.

32. D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. *Aliment Pharmacol Ther* 1998;12(5):419-24.

33. D'Haens G, Hommes D, Engels L, Baert F, Waaij L, Connor P, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. *Alimentary Pharmacology and Therapeutics* 2006;24(7):1087-97.

34. D'Haens G, Vermeire S, Assche G, Noman M, Aerden I, Olmen G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. *Gastroenterology* 2008;135(4):1123-9.
35. D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Once-daily MMX<sup>®</sup> mesalamine for endoscopic maintenance of remission of ulcerative colitis. *American Journal of Gastroenterology* 2012;107(7):1064-77.
36. d'Albasio G, Paoluzi P, Campieri M, Porro GB, Pera A, Prantera C, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. *American Journal of Gastroenterology* 1998;93(5):799–803.
37. Daghighzadeh H, Naji F, Afshar H, Sharbafchi MR, Feizi A, Maroufi M, et al. Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study. *Journal of Research in Medical Sciences* 2015;20:595-601.
38. Danese S, Rudzinski J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. *Gut* 2014;64(2):243-9.
39. Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. *Gut* 2004; Vol. 53:1646-51.
40. Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2006; Vol. 23:1415-25.

41. Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). *Gut* 2014;63(2):292-9.
42. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. *Clinical Gastroenterology and Hepatology* 2009;7(7):762-9.
43. Escher JC, European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. *Eur J Gastroenterol Hepatol* 2004;16(1):47-54.
44. Ewe K, Bottger T, Buhr HJ, Ecker KW, Otto HF. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. *European Journal of Gastroenterology and Hepatology* 1999;11(3):277-82.
45. Farup PG, Hinterleitner TA, Lukás M, Hébuterne X, Rachmilewitz D, Campieri M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. *Inflammatory Bowel Diseases* 2001;7(3):237-42.
46. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's

disease. New England Journal of Medicine 2000;342(22):1627-32. [PUBMED:  
2000197470]

47. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine 2005;352(24):2499-507.
48. Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008;299(14):1690-7. - Study 1
49. Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008;299(14):1690-7. - Study 2
50. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2013;369(8):699-710. – Study 1
51. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2013;369(8):699-710. – Study 2
52. Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JW, Rutgeerts P, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145:149-57.
53. Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone



in patients with Crohn's disease. *Gastroenterology* 2014;146(3):681-8. [PUBMED: 24269926]

54. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. *New England Journal of Medicine* 2016. – Study 1
55. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. *New England Journal of Medicine* 2016. – Study 2
56. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. *New England Journal of Medicine* 2016. – Study 3
57. Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group. *Alimentary Pharmacology and Therapeutics* 1998;12(2):175-83.
58. Florent C, Cortot A, Quandale P, Sahmound T, Modigliani R, Sarfaty E, et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). *European Journal of Gastroenterology & Hepatology* 1996;8(3):229-33.
59. Flourie B, Hagège H, Tucacat G, Maetz D, Hébuterne X, Kuyvenhoven JP, et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2013;37(8):767-75.

60. Forbes A, Al-Damluji A, Ashworth S, Bramble M, Herbert K, Ho J, et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2005;21(9):1099-104.
61. Franchis R, Omodei P, Ranzi T, Brignola C, Rocca R, Prada A, et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. *Alimentary Pharmacology and Therapeutics* 1997;11:845-52.
62. Gassull MA, Fernandez-Banares F, Cabre E, Papo M, Giaffer MH, Sanchez-Lombrana JL, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. *Gut* 2002;51 (2):164–8.
63. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn's disease. *New England Journal of Medicine* 2003;348(1):24-32.
64. Gibson PR, Fixa B, Pekárková B, Bátorvský M, Radford-Smith G, Tibitanzl J, et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2006;23(7):1017-26.
65. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000; 119(2):305–9.

66. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Gastroenterology* 2003; 124(5):1202–9
67. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al. A randomized placebo-controlled trial of humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. *Gastroenterology* 2001;121(2):268–74.
68. Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. *Alimentary Pharmacology and Therapeutics* 1998;12:1207-16.
69. Green JRB, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, et al. Balsalazide is more effective and better tolerated than mesalazine in the treatment of acute ulcerative colitis. *Gastroenterology* 1998;114(1):15-22.
70. Green JRB, Mansfield JC, Gibson JA, Kerr GD, Thornton PC. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2002;16(1):61-8.
71. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. *Gastroenterology* 1996;110(1):45-51.

72. Grogan JL, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric Crohn's disease: A double-blind randomized controlled trial with two years follow-up. *Inflammatory Bowel Diseases* 2012;18(2):246–53.
73. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. *Eur J Gastroenterol Hepatol*1996;8(9):905-9.
74. Gross V, Andus T, Ecker KW, Raedler A, Loeschke K, Plauth M, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. *Gut* 1998;42(4):493-6.
75. Gross V, Buganic I, Belousova EA, Mikhailova TL, Kupcinkas L, Kiudelis G, et al. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial. *Journal of Crohn's and Colitis* 2011;5(2):129-138.
76. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. *Clinical Gastroenterology and Hepatology* 2006;4(12):1502-6.
77. Hanai H, Iida T, Takeuchi K, Arai H, Arai O, Abe J, et al. Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease. *Digestive and Liver Disease* 2012;44(8):649-54.

78. Hanauer SB, Sninsky CA, Robinson M, Powers BJ, McHattie JD, Mayle JE, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. *Annals of Internal Medicine* 1996;124:204-11.
79. Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. *American Journal of Gastroenterology* 2000;95(7): 1749–54.
80. Hanauer S, Korelitz B, Rutgeerts P, Peppercorn M, Thisted R, Cohen R, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. *Gastroenterology* 2004;127(3):723-9.
81. Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. *Alimentary Pharmacology and Therapeutics* 2005;21(4):363-71.
82. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. *Canadian Journal of Gastroenterology* 2007;21(12):827-34.
83. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF, and the European Zileuton Study Group for Ulcerative Colitis. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. *Gastroenterology* 1997;112:718-24.
84. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, et al. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with

800 mg three times daily for maintenance of remission in ulcerative colitis.

Inflammatory Bowel Disease 2012;18(10):1885-93.

85. Hellers G, Cortot A, Jewell D, Leijonmarck CE, Lofberg R, Malchow H, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. *Gastroenterology* 1999;116(2):294-300.
86. Hiwatashi N, Suzuki Y, Mitsuyama K, Munakata A, Hibi T. Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. *Journal of Gastroenterology* 2011;46(1):46-56.
87. Ito H, Iida M, Matsumoto T, Suzuki Y, Sasaki H, Yoshida T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. *Inflammatory Bowel Diseases* 2010;16(9):1567-74.
88. Jiang XL, Cui HF. Different therapy for different types of ulcerative colitis. *World Journal of Gastroenterology* 2004;10(10):1513-20.
89. Jiang XL, Cui HF, Gao J, Fan H. Low-dose Infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis. *Journal of Clinical Gastroenterology* 2015;49(7):582-8.
90. Joelsson M, Andersson M, Bark T, Gullberg K, Hallgren T, Jiborn H, et al. Allopurinol as prophylaxis against pouchitis following ileal pouch-anal anastomosis for ulcerative colitis. A randomized placebo-controlled double-blind study. *Scandinavian Journal of Gastroenterology* 2001; 36 (11): 1179–84.

91. Jong DJ, Bac DJ, Tan G, Boer SY, Grabowsky IL, Jansen JB, et al. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission. *Netherlands Journal of Medicine* 2007;65(9):339-45.
92. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. *Gastroenterology* 2007; Vol. 132:66-75.
93. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. *Gut* 2008;57(7):893-902.
94. Kane S, Holderman W, Jacques P, Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial. *Patient Preference and Adherence* 2008;2(2):253-8.
95. Kjaer MD, Qvist N, Nordgaard-Lassen I, Christensen LA, Kjeldsen J. Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial. *Scandinavian Journal of Gastroenterology* 2019;54(2): 188–93.
96. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, Sargramostim in Crohn's Disease Study Group. Sargramostim for active Crohn's disease. *New England Journal of Medicine* 2005;352(21):2193-201.
97. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral *Escherichia coli* preparation and mesalazine in maintaining remission of ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 1997;11(5):853-8.

98. Kruis W, Brandes JW, Schreiber S, Theuer D, Krakamp B, Schutz E, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 1998;12(8):707-15.
99. Kruis W, Schreiber S, Theuer D, Brandes JW, Schutz E, Howaldt S, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. *Gut* 2001;49(6):783-9.
100. Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Faszczyk M, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. *Clinical Gastroenterology and Hepatology* 2003;1(1):36-43.
101. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic *Escherichia coli* Nissle 1917 is as effective as with standard mesalazine. *Gut* 2004;53(11):1617-23.
102. Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. *Gut* 2009;58(2):233-40.
103. Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátorovský M, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2011;33(3):313-22.



104. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of *Lactobacillus rhamnosus* GG on ileal pouch inflammation and microbial flora. *Alimentary Pharmacology and Therapeutics* 2003; 17 (4):509–15.
105. Leiper K, Woolner J, Mullan MM, Parker T, van der Vliet M, Fear S, et al. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. *Gut* 2001;49(6):790–4.
106. Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. *Alimentary pharmacology & therapeutics* 2008;27(12):1233-9.
107. Leiper K, Martin K, Ellis A, Subramanian S, Watson AJ, Christmas SE, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. *Gut* 2011; Vol. 60:1520-6.
108. Lémann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. *Gastroenterology* 2005;128(7):1812-8.
109. Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. *American Journal of Gastroenterology* 2002;97(6):1398-407.
110. Levine A, Weizman Z, Broide E, Shamir R, Shaoul R, Pacht A, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. *J Pediatr Gastroenterol Nutr* 2003;36(2):248-52.

111. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. *Gastroenterology* 2008;134:688-95.
112. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. *Clinical Gastroenterology and Hepatology* 2007; Vol. 5:95-102.
113. Lichtenstein GR, Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. *Alimentary Pharmacology and Therapeutics* 2010;32(8):990-9.
114. Lochs H, Mayer M, Fleig W, Mortensen PB, Bauer P, Genser D, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. *Gastroenterology* 2000;118(2):264-73.
115. Lofberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. *Gut* 1996;39(1):82-6.
116. Löfberg R, Danielsson Å, Suhr O, Nilsson Å, Schiöler R, Nyberg A, et al. Oral budesonide versus prednisone in patients with active extensive and left-sided ulcerative colitis. *Gastroenterology* 1996;110(6):1713-8.

117. Lomer MC, Grainger SL, Ede R, Catterall AP, Greenfield SM, Cowan RE, et al. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. *European Journal of Gastroenterology & Hepatology* 2005;17(3):377-84. [PUBMED: 15716665]
118. Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. *Scandinavian Journal of Gastroenterology* 1996;31(8):778-85. [PUBMED: 8858747]
119. Madisch A, Miehlike S, Eichele O, Mrwa J, Bethke B, Kuhlisch E, et al. *Boswellia serrata* extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled multicenter trial. *International Journal of Colorectal Disease* 2007;22(12):1445-51.
120. Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis P, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. *American Journal of Gastroenterology* 2001;96(6):1807-15.
121. Mahmud N, Kamm MA, Dupas JL, Jewell DP, O'Morain CA, Weir DG, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. *Gut* 2001;49(4):552-6.

122. Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2002;16(2):207-15.
123. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn's disease. *New England Journal of Medicine* 2004;351(20):2069-79.
124. Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2002;16(1):69-77.
125. Mantzaris GJ, Petraki K, Sfakianakis M, Archavlis E, Christidou A, Chadio-Iordanides H, et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. *Clinical Gastroenterology and Hepatology* 2003;1(2):122-8.
126. Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. *Inflammatory Bowel Diseases* 2009;15(3):375-82.
127. Marakhouski Y, Fixa B, Holoman J, Hulek P, Lukas M, Batovsky M, et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2005;21(2):133-40.

128. Marteau P, Crand J, Foucault M, Rambaud JC. Use of mesalazine slow release suppositories 1g three times per week to maintain remission of ulcerative proctitis: a randomized double blind placebo controlled multicentre study. *Gut* 1998;42(2):195–9.
129. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. *Gut* 2005; Vol. 54:960-5.
130. Maté-Jiménez J, Hermida C, Cantero Perno J, Moreno Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroiddependent inflammatory bowel disease. *European Journal of Gastroenterology and Hepatology* 2000;12:1227–33.
131. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. *Gut* 2014;63:442-50.
132. Miehlike S, Heymer P, Bethke B, Baestlein E, Meier E, Bartram HP, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. *Gastroenterology* 2002;123(4):978-84.
133. Miehlike S, Madisch A, Bethke B, Morgner A, Kuhlisch E, Henker C, et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, placebo controlled, double-blind trial. *Gastroenterology* 2008;135:1510-16.

134. Miehlike S, Madisch A, Kupcinskis L, Petrauskas D, Böhm G, Marks H, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. *Gastroenterology* 2014;146(4):1222-30.
135. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. *Gut* 2004; 53 (1):108–14.
136. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology* 2015;149(1):102-9.
137. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. *Gastroenterology* 1996;110:688-93.
138. Münch A, Bohr J, Miehlike S, Benoni C, Olesen M, Öst A, et al. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: A randomised, placebo-controlled, 12-month trial. *Gut* 2016;65:47-56.
139. Munck LK, Kjeldsen J, Philipsen E, Fischer Hansen B. Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study. *Scandinavian Journal of Gastroenterology* 2003;38(6):606-10.
140. Musch E, Andus T, Kruis W, Raedler A, Spehlmann M, Schreiber S, et al. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. *Clinical Gastroenterology and Hepatology* 2005;3(6):581-6.

141. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. *Clinical Gastroenterology and Hepatology* 2013;11(10):1276–80.
142. Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn's Disease, a randomized controlled trial. *Digestive Diseases and Sciences* 2017;62: 1615-20.
143. Nikolaus S, Rutgeerts P, Fedorak R, Steinhart AH, Wild GE, Theuer D, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. *Gut* 2003;52(9):1286-90.
144. Ockenga J, Borchert K, Stuber E, Lochs H, Manns MP, Bischoff SC. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. *European Journal of Clinical Nutrition* 2005; 59 (11):1302–9.
145. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. *Gut* 2006;55:1255-62.
146. Ogata H, Kato J, Hirai F, Hida N, Matsui T, Matsumoto T, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. *Inflammatory Bowel Diseases* 2012; Vol. 18:803–8.

147. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. *Gastroenterology* 1996; Vol. 110:1416-21.
148. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. *Inflammatory Bowel Diseases* 2015;21(6):1329-40.
149. Panes J, Esteve M, Cabre E, Hinojosa J, Andreu M, Sans M, et al. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. *Gastroenterology* 2000;119(4):903-8. [PUBMED: 11040177].
150. Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. *Gastroenterology* 2013;145(4):766-74.
151. Paoluzi OA, Iacopini F, Pica R, Crispino P, Marcheggiano A, Consolazio A, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. *Alimentary Pharmacology and Therapeutics* 2005;21(9):1111-9.
152. Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, Bogaerde J, Samuel D, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet* 2017;389(10075):1218-28.
153. Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. *Inflammatory Bowel Diseases* 2012;18(8):1470-9.



154. Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J, Rachmilewitz D, et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon- $\beta$ -1a in moderately active ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2008;28(6):758-67.
155. Pontes C, Vives R, Torres F, Panes J. Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. *Inflammatory Bowel Diseases* 2014;20(11):2004–12.
156. Prantera C, Zannoni F, Scribano MI, Berto E, Andreoli A, Kohn A, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. *American Journal of Gastroenterology* 1996;91(2):328-32.
157. Prantera C, Cottone M, Pallone F, Annese V, Franze A, Cerutti R, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. *Gastroenterology* 1999;116(3):521-6.
158. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. *Alimentary Pharmacology & Therapeutics* 2006;23(8):1117-25.
159. Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. *Alimentary Pharmacology and Therapeutics* 2009;30(9):908-18.

160. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano MI, Gionchetti P. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. *Gastroenterology* 2012;142(3):473-81.
161. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott I D, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. *Gut* 2003;52:998-1002.
162. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. *Inflammatory Bowel Diseases* 2008; 14 (5):662–8.
163. Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. *American Journal of Gastroenterology* 2002;97(12):3078-86.
164. Raedler A, Behrens C, Bias P. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis -- results from a randomized-controlled trial. *Alimentary Pharmacology and Therapeutics* 2004;20(11-12):1353-63.
165. Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. *American Journal of Gastroenterology* 2008;103(9):2284-92.

166. Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. *Gut* 2010;59(6):752-9.
167. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. *Gut* 2011; Vol. 60:780-7.
168. Reinisch W, Panes J, Khurana S, Toth G, Hua F, Comer G, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase Ila randomised multicentre study. *Gut* 2015;64(6):894-900.
169. Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. *Alimentary Pharmacology and Therapeutics* 2017;46(2):142-9.
170. Romano C, Cucchiara S, Barabino A, Annese V, Sferlazzas C. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. *World Journal of Gastroenterology* 2005;11(45):7118-21.
171. Rossen NG, Fuentes S, Spek MJ, Tissen JG, Duflou A, Lowenberg M, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. *Gastroenterology* 2015;149(1):110-8.

172. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *New England Journal of Medicine* 2005; Vol. 353:2462-76. – Study 1.
173. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *New England Journal of Medicine* 2005; Vol. 353:2462-76. – Study 2
174. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, et al. A randomised phase i study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. *Gut* 2013;62(8):1122-30.
175. Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. *Alimentary Pharmacology & Therapeutics* 2015;42(5):504-14.
176. Sakurai T, Matsui T, Yao T, Takagi Y, Hirai F, Aoyagi K, et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn's disease: a randomized, controlled trial comparing nutrient formulas. *JPEN Journal of Parenteral and Enteral Nutrition* 2002;26(2):98–103
177. Sambuelli A, Boerr L, Negreira S, Gil A, Camartino G, Huernos S, et al. Budesonide enema in pouchitis - A double-blind, double-dummy, controlled trial. *Alimentary Pharmacology and Therapeutics* 2002; 16 (1):27–34.

178. Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. *Alimentary Pharmacology & Therapeutics* 2003;17:1355–64.
179. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance I, et al. Natalizumab induction and maintenance therapy for Crohn's disease. *New England Journal of Medicine* 2005;353(18):1912–25. – Study 1
180. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance I, et al. Natalizumab induction and maintenance therapy for Crohn's disease. *New England Journal of Medicine* 2005;353(18):1912–25. – Study 2
181. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. *Gastroenterology* 2008;135(4):1130-41.
182. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. *Gastroenterology* 2009;137(6):1934-43.
183. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. *Gastroenterology* 2010;138(4):1286-96.

184. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, et al. Abatacept for Crohn's disease and ulcerative colitis. *Gastroenterology* 2012; Vol. 143:62–9. – Study 1
185. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, et al. Abatacept for Crohn's disease and ulcerative colitis. *Gastroenterology* 2012; Vol. 143:62–9. – Study 2
186. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, et al. Abatacept for Crohn's disease and ulcerative colitis. *Gastroenterology* 2012; Vol. 143:62–9. – Study 3
187. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, et al. Abatacept for Crohn's disease and ulcerative colitis. *Gastroenterology* 2012; Vol. 143:62–9. – Study 4
188. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. *New England Journal of Medicine* 2012;367(16):1519-28. – Study 1
189. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. *New England Journal of Medicine* 2012;367(16):1519-28. – Study 2
190. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. *New England Journal of Medicine* 2012;367:616-24.

191. Sandborn WJ, Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2012;142(2):257-65.
192. Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, et al. Once-daily Budesonide MMX<sup>®</sup> extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: Results from the CORE 1 study. *Gastroenterology* 2012;143(5):1218-26.
193. Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, et al. Randomised clinical trial: the safety and tolerability of *Trichuris suis ova* in patients with Crohn's disease. *Alimentary Pharmacology and Therapeutics* 2013;38(3):255-63.
194. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2014;146:85-95.
195. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2014;146:85-95.
196. Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, et al. Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, Phase 2b study. *Journal of Crohn's and Colitis* 2016;E-pub ahead of print:1-11.

197. Sands BE, Sandborn WJ, Creed TJ, Dayan CM, Dhanda AD, Assche GA, et al. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. *Gastroenterology* 2012; Vol. 143:356-64.e1.
198. Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzone L, Mazza F. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. *American Journal of Gastroenterology* 2013;108:1731-42.
199. Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. *American Journal of Gastroenterology* 2009; Vol. 104:1452-9.
200. Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. *Clinical Gastroenterology and Hepatology* 2005;3(2):113-21.
201. Schreiber S, Keshavarzian A, Isaacs KL, Schollenberger J, Guzman JP, Orlandi C, et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. *Gastroenterology* 2007; Vol. 132:76-86.
202. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. *Gastroenterology* 2007;132(7):2313-19.
203. Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active



Crohn's disease: a randomized placebo-controlled trial. *Digestive Diseases and Sciences* 2011;56(7):2088-97.

204. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. *Indian Journal of Gastroenterology* 2000;19(1):14-6.

205. Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. *Journal of Gastroenterology* 2002;37(4):270-4.

206. Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. *Indian Journal of Gastroenterology* 2003;22(3):79-81.

207. Steinhart AH, Hiruki T, Brzezinski A, Baker JP. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. *Alimentary Pharmacology and Therapeutics* 1996; Vol. 10:729-36.

208. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. *Gastroenterology* 2002;123(1):33-40.

209. Strisciuglio C, Giannetti E, Martinelli M, Sciorio E, Staiano A, Miele E. Does cow's milk protein elimination diet have a role on induction and maintenance of remission in children with ulcerative colitis?. *Acta Paediatrica* 2013;102(6):e273-8. [PUBMED: 23445275]

210. Summers RW, Elliott DE, Urban JF, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. *Gastroenterology* 2005;128(4):825-32.
211. Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. *Gastroenterology* 1997;112(4):1069-77.
212. Suzuki Y, Motoya S, Takazoe M, Kosaka T, Date M, Nii M, Hibi T. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study. *J Crohns Colitis* Apr 2013;7(3):239-47. [PUBMED: 22766525]
213. Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson A, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. *Journal of Gastroenterology* 2014;49(2):283-294.
214. Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial. *Alimentary Pharmacology & Therapeutics* 2006;24(9):1333-40.
215. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. *Gastroenterology* 2007;132(5):1672-83.

216. Terrin G, Canani RB, Ambrosini A, Viola F, De Mesquita MB, Di Nardo G, et al. A semielemental diet (Pregomin) as primary therapy for inducing remission in children with active Crohn's disease. *Italian Journal of Pediatrics* 2002;28 (5):401–5.
217. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, et al. A comparison of budesonide and mesalamine for active Crohn's disease. *International Budesonide-Mesalamine Study Group. New England Journal of Medicine* 1998;339(6):370-4.
218. Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF, et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. *Gut* 2003;52(12):1728-33.
219. Travis S, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, et al. Once-daily budesonide MMX in active mild-to-moderate ulcerative colitis: results from the randomised CORE II study. *Gut* 2014;63(3):433-41.
220. Tremaine WJ, Sandborn WJ, Wolff BG, Carpenter HA, Zinsmeister AR, Metzger PP. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. *Alimentary Pharmacology and Therapeutics* 1997; 11 (6):1041–6.
221. Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, et al. Budesonide CIR capsules one or twice daily in active Crohn's disease. A randomized placebo controlled study in the USA. *Am J Gastroenterol* 2002;97(7):1748-54.

222. Triantafyllidis JK, Stamataki A, Karagianni V, Gikas A, Malgarinos G. Maintenance treatment of Crohn's disease with a polymeric feed rich in TGF-beta. *Annals of Gastroenterology* 2010;23(2):113-8.
223. Tromm A, Bungani I, Tomsová E, Tulassay Z, Luká M, Kykal J, Bátorvský M, Fixa B, Gabalec L, Safadi R, Kramm H, J. Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. *Gastroenterology* 2011;140(2):425-34.
224. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. *Medical Science Monitor* 2004;10(11):PI126-31.
225. Tursi A, Giorgetti GM, Brandimarte G, Elisei W, Aiello F. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study. *Med Sci Monit* 2006;12(6):PI29-32.
226. Valentine JF, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P, et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. *Gut* 2009;58(10):1354-62.
227. Verma S, Brown S, Kirkwood B, Giaffer MH. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. *American Journal of Gastroenterology* 2000;95(3):735-9.

228. Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease?. *Scandinavian Journal of Gastroenterology* 2001;36(4):383-8.
229. Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: A randomised study. *Gut* 2011;60:1068-75.
230. Vermeire S, O'Byrne S, Keir M, Williams M, Lu T, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis:a randomised, controlled, phase 2 trial. *Lancet* 2014;384(9940):309-18.
231. Vilien M, Dahlerup JF, Munck LK, Nørregaard P, Grønbaek K, Fallingborg J. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: Increased relapse rate the following year. *Alimentary Pharmacology and Therapeutics* 2004;19(11):1147-52.
232. Vrij AA, Oberndorff-Klein-Woolthuis A, Dijkstra G, Jong AE, Wagenvoord R, Hemker HC, et al. Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. *J Thromb Thrombolysis* 2007;24(2):175-82. [PUBMED: 17308963].
233. Watanabe M, Hanai H, Nishino H, Yokoyama T, Terada T, Suzuki Y. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. *Inflammatory Bowel Diseases* 2013;19(8):1681-90.

234. Watanabe M, Nishino H, Sameshima Y, Ota A, Nakamura S, Hibi T. Randomised clinical trial: Evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - A placebo-controlled study. *Alimentary Pharmacology and Therapeutics* 2013; Vol. 38:264-73.
235. Wenzl HH, Primas C, Novacek G, Teml A, Öfferlbauer-Ernst A, Högenauer C, et al. Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease. *Digestive Diseases and Science* 2015;60(5):1414-23.
236. West RL, Woude CJ, Hansen BE, Felt-BersmaRJF, Tilburg AJP, Drapers JAG, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: A double-blind placebo-controlled study. *Alimentary Pharmacology and Therapeutics* 2004;20(11-12):1329-36.
237. Wildt S, Munck LK, Vinter-Jensen L, Hansen BF, Nordgaard-Lassen I, Christensen S, et al. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with *Lactobacillus acidophilus* and *Bifidobacterium animalis* subsp. *Lactis*. *Inflammatory Bowel Diseases* 2006;12(5):395-401.
238. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with *Lactobacillus acidophilus* La-5 and *Bifidobacterium animalis* subsp. *lactis* BB-12 for maintenance of remission in ulcerative colitis. *Journal of Crohn's and Colitis* 2011;5(2): 115–21.
239. Yasueda A, Mizushima T, Nezu R, Sumi R, Tanaka M, Nishimura J, et al. The effect of *Clostridium butyricum* MIYAIRI on the prevention of pouchitis and alteration of the

microbiota profile in patients with ulcerative colitis. *Surgery Today* 2016;46(8):939–49.

[PUBMED: 26510664]

240. Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, et al. Safety and efficacy of AJM300, an oral antagonist of  $\alpha 4$ I integrin, in induction therapy for patients with active ulcerative colitis. *Gastroenterology* 2015;149:1775-83.
241. Zezos P, Papaioannou G, Nikolaidis N, Patsiaoura K, Papageorgiou A, Vassiliadis T, et al. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. *Aliment Pharmacol Ther* 2006;23(10):1443-53. [PUBMED: 16669959].
242. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. *Alimentary Pharmacology and Therapeutics* 2006;23(11):1567-74.